February 24, 2021 -- Yokogawa Electric has entered into a partnership with Integrated Commissioning and Qualification Consultants (ICQ) in which ICQ will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa's bioreactor systems and related products in the U.S.
The COVID-19 pandemic has increased the demand for infrastructure in developing and manufacturing monoclonal antibody drugs and products that require mammalian cell bioreactor technologies.
Under the agreement, Yokogawa will leverage ICQ services to launch its new bioprocess technologies in the U.S., including its advanced control bioreactor system (BR1000). The company's bioreactor automates glucose control through in-line sensing, model predictive control software, and automated feed.
Copyright © 2021 scienceboard.net